UNSPSC 51285604: Delmopinol hydrochloride

This classfication denotes a surface-active agent with the molecular formula C16H33NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SRE423V9Z9, chemically known as 4-morpholineethanol, 3-(4-propylheptyl)-, hydrochloride (1:1), but more generally known as delmopinol hydrochloride, which bears U.S. National Institutes of Health Compound Identifier 57337. European Medicines Agency schedules delmopinol hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06956MIG.

Most nations, for tariff purposes, schedule delmopinol hydrochloride under HS 29349990. SMILES: CCCC(CCC)CCCC1COCCN1CCO.CL.

UNSPSC 51285604 Delmopinol hydrochloride is a Commodity code used to tag pharmaceutical procurement, though recent state and local contract opportunities show limited activity directly tied to this specific antimicrobial agent. The code nominally covers delmopinol hydrochloride, an oral rinse and anti-plaque pharmaceutical ingredient, but the most recent opportunities posted under or near this classification reflect broader pharmaceutical warehouse and drug-supply contracting by state health departments and county health systems. State and local governments procure pharmaceutical products through piggyback agreements with established cooperative purchasing consortiums such as MMCAP Infuse, which aggregate purchasing power and leverage awarded vendor relationships to stock medications for public health emergency response, routine clinical supply, and community health initiatives. These procurements typically specify drug products by brand or generic name, strength, package count, expiration period, and delivery schedule, with contract terms ranging from one to three years and renewal options.

The Illinois Department of Public Health and Seminole County, Florida represent the issuing-body mix on record, reflecting state-level pharmacy supply coordination and county-level community health procurement. The Illinois contract awarded to Chartwell Rx LLC in August 2026 was a $2,999,999.11 piggyback pharmaceutical warehouse order covering Doxycycline Hyclate and Ciprofloxacin Hydrochloride through an Invitation for Bid process with a 12-month initial term and two renewal options. Seminole County's June 2026 IFB (IFB60459723LAS) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year contract with a one-year renewal option. Geographic activity centers on Illinois and Florida based on these records. Neither opportunity was an open solicitation at the time of posting; the Illinois award was completed and the Seminole County bid timeline included a due date that predates the current reference date, indicating the RFP cycle has closed.